focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

5 Oct 2009 07:00

RNS Number : 1958A
Immunodiagnostic Systems Hldgs PLC
05 October 2009
 



 

Immunodiagnostic Systems Holdings plc

Trading update

Immunodiagnostic Systems Holdings plc ("IDS" or "the Company"), a leading producer of diagnostic testing kits for the clinical and research markets, announces a trading update for the six month period to 30 September 2009, prior to the release of its half-yearly report on Monday, 30 November 2009.

Turnover from continuing operations for the period is 56% ahead of the comparative period for last year at £16.9 million (2008: £10.8 million) and 20% ahead of 2008 H2 on a like for like basis. Revenues have increased in all direct sales territories with substantial growth in the USAFrance and Germany. Sales of our Vitamin D products continue to grow at an impressive rate, having doubled compared to same period last year.

The company has made progress in both sales and placements of our automated instrument the IDS-iSYS following its launch at the end of February this yearWe have also launched three automated products; 25 Hydroxy vitamin D at the end of February, P1NP in July and HGH in September. We have direct reagent rental accounts in the UK, FranceGermanyAustria 

and Switzerland and have made instrument sales in AustraliaCanadaFinlandItalySpainFrance and Switzerland.

The roll out of the IDS-iSYS is in its formative stages, and although initial machine sales are a little lower than anticipated, it is pleasing to report that revenue per machine is ahead of expectations. We expect the rate of sales and placements to increase in H2 following the increase in the number of iSYS evaluation sites towards the end of H1, the new agreement with Technogenetics (announced today on RNS Reach) under which we will supply OEM instruments and reagents to them, and, subject to the timing of FDA approval later this year, the planned US launch of the iSYS system.

Overall trading remains in line with management expectations and the Board remains confident going forward that it can continue to execute its plans for the current year.

Enquiries:

Immunodiagnostic Systems Holdings Plc

Tel: 0191 519 0660

Roger Duggan, CEO

Paul Hailes, Finance Director

Brewin Dolphin Investment Banking

Tel: 0845 213 4730

Andrew Emmott

Sean Wyndham-Quin

Walbrook PR Ltd

Tel: 020 7933 8787

Paul McManus

Mob: 07980 541 893

paul.mcmanus@walbrookpr.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTILFLTIRLSIIA
Date   Source Headline
17th May 20217:00 amRNSOffer for Immunodiagnostic Systems Holdings Plc
16th Apr 20217:00 amRNSFY21 Trading Update
29th Mar 20217:00 amRNSFDA EUA for automated IgG SARS-CoV-2 assay
27th Nov 20209:05 amRNSSecond Price Monitoring Extn
27th Nov 20209:00 amRNSPrice Monitoring Extension
27th Nov 20207:00 amRNSLaunch of SARS-CoV-2 Antigen Rapid Tests
20th Nov 20206:22 pmRNSInterim Results - period ended 30 September 2020
26th Oct 20209:05 amRNSSecond Price Monitoring Extn
26th Oct 20209:00 amRNSPrice Monitoring Extension
23rd Oct 20204:35 pmRNSH1 Trading Update
9th Oct 20207:00 amRNSAssay to detect IgM SARS-CoV-2 antibodies launch
16th Sep 20207:00 amRNSNew TDM assays launched for use on the IDS-iSYS
14th Sep 20202:39 pmRNSDirector/PDMR Shareholding
27th Aug 20207:00 amRNSSARS-CoV-2 manufacturing agreement
13th Aug 20204:40 pmRNSSecond Price Monitoring Extn
13th Aug 20204:35 pmRNSPrice Monitoring Extension
13th Aug 20207:00 amRNSAutomated IgM assay to detect SARS-CoV-2
4th Aug 20204:18 pmRNSLaunch of automated IDS Cortisol assay
23rd Jul 20202:57 pmRNSResults of AGM
23rd Jul 20207:00 amRNSAGM Statement
17th Jul 202010:40 amRNSDirector/PDMR Shareholding
16th Jul 20201:45 pmRNSDirector/PDMR Shareholding
30th Jun 20209:05 amRNSSecond Price Monitoring Extn
30th Jun 20209:00 amRNSPrice Monitoring Extension
30th Jun 20207:00 amRNSLaunch of assay to detect SARS-CoV-2 antibodies
17th Jun 20208:35 amRNSPublication of Annual Report and Accounts
17th Jun 20207:00 amRNSFinal Results
12th Jun 20209:06 amRNSSecond Price Monitoring Extn
12th Jun 20209:00 amRNSPrice Monitoring Extension
12th Jun 20207:00 amRNSAutomated assay to detect SARS-CoV-2 antibodies
17th Apr 20204:35 pmRNSFY20 Trading Update
31st Mar 202011:00 amRNSDirector/PDMR Shareholding
21st Feb 20204:11 pmRNSDirector/PDMR Shareholding
21st Feb 20209:11 amRNSDirector/PDMR Shareholding
20th Feb 20204:49 pmRNSDirector/PDMR Shareholding
22nd Nov 20194:35 pmRNSHalf-year Report
18th Oct 20194:35 pmRNSTrading Statement
25th Jul 20193:34 pmRNSResult of AGM
25th Jul 20197:00 amRNSAGM Statement
11th Jul 20192:16 pmRNSDirector/PDMR Shareholding
5th Jul 201910:02 amRNSDirector/PDMR Shareholding
19th Jun 20197:05 amRNSPublication of Annual Report and Accounts
19th Jun 20197:00 amRNSFinal Results
22nd May 20192:05 pmRNSSecond Price Monitoring Extn
22nd May 20192:00 pmRNSPrice Monitoring Extension
18th Apr 20194:35 pmRNSFY2019 Trading Update
12th Mar 201911:55 amRNSChange of Auditor
7th Jan 20198:20 amRNSDirector/PDMR Shareholding
18th Dec 20181:42 pmRNSDirector/PDMR Shareholding
6th Dec 20185:13 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.